Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 GH001 in Bipolar II Depression
2021-006861-39Phase 2Terminated
- Sponsor
- GH Research PLC
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mebufotenin in Bipolar II disorder (BP-II), sponsored by GH Research PLC. Primary endpoint: Onset and 7-day durability of antidepressant effects of GH001. Started Mar 2022; status: terminated.
02
Drugs
mebufotenin
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on 2021-006861-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006861-39.